Embecta Corp. (NASDAQ:EMBC) saw its shares climb 2.32% in after-hours trading Friday, following the release of strong third-quarter results that exceeded analyst expectations thanks to effective commercial execution and favorable customer order timing.
For the fiscal third quarter ending June 30, 2025, the global diabetes care company posted adjusted earnings of $1.12 per share, well above the consensus estimate of $0.77. Revenue reached $295.5 million, topping the anticipated $278.15 million and reflecting an 8.4% year-over-year increase. U.S. revenues rose 11.6%, while international sales increased 5.0%.
“Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders,” said Devdatt Kurdikar, President and CEO of embecta. “Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics.”
The company’s adjusted operating income margin expanded to 36.9% from 30.6% in the same period last year, while the adjusted EBITDA margin improved to 44.3% from 36.4%.
Following the solid quarter, embecta raised its full-year guidance, now expecting adjusted earnings between $2.90 and $2.95 per share, above the analyst consensus of $2.83. Revenue forecasts were also tightened to a range of $1.078 billion to $1.085 billion, closely aligned with the $1.08 billion consensus.
During the quarter, embecta completed its separation program by implementing its ERP system and operationalizing distribution centers and shared services in India. The company also advanced efforts to expand availability of appropriately sized GLP-1 retail packaging for weekly injection therapies.
“We remain focused on executing on the value creation drivers we highlighted at our recent Analyst and Investor Day, including our long-term goal of transforming embecta into a diversified medical supplies company,” Kurdikar added.
The company announced a quarterly dividend of $0.15 per share, payable on September 15, 2025, to shareholders of record as of August 29, 2025.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.